David Page, MD
Dr. David Page is a medical oncologist and clinical investigator at the Providence Cancer Institute in Portland, Oregon. His area of expertise is in the field of breast cancer immunotherapy.
He completed a Bachelor’s of the Arts at the University of Chicago, a medical doctorate at Northwestern University, followed by internal medicine residency at Columbia University / New York Presbyterian and medical oncology fellowship at Memorial Sloan Kettering Cancer Center in New York City.
He has conducted and published outcomes of numerous investigator-initiated trials, including trials combining immune checkpoint blockade with chemotherapy, radiotherapy, and novel targeted/immune therapies in breast cancer, both in the curative and metastatic setting. He also has served on various immunotherapy-related committees, including the NCI Breast Immuno-oncology task force, the SITC Breast Immunotherapy expert panel, and the SITC multispectral immunoflourescence working group.
Financial relationships
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:MerckTopic:IITDate added:01/11/2023Date updated:12/21/2023Relationship end date:01/01/2024
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:BMSTopic:IITDate added:01/11/2023Date updated:12/21/2023Relationship end date:01/01/2024
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:Brooklyn ImmunotherapeuticsTopic:IITDate added:01/11/2023Date updated:12/21/2023Relationship end date:01/01/2024
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:WindMILTopic:IITDate added:01/11/2023Date updated:12/21/2023Relationship end date:06/01/2022
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:NovartisTopic:Speaker BureauDate added:01/11/2023Date updated:12/21/2023
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:GenentechTopic:Speaker BureauDate added:01/11/2023Date updated:12/21/2023
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:OncocyteTopic:Speaker BureauDate added:01/11/2023Date updated:12/21/2023
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:MerckTopic:ConsultantDate added:01/11/2023Date updated:12/21/2023
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:Brooklyn ImmunotherapeuticsTopic:ConsultantDate added:01/11/2023Date updated:12/21/2023
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:Sanford Burnham PresbysTopic:ConsultantDate added:01/11/2023Date updated:12/21/2023